According to a large clinical trial, CD8+ T cell infiltration in breast cancer is associated with a reduced relative risk of death from the disease, and tumor lymphocyte infiltration improves risk stratification in patients with ER-negative and ER-positive HER2-positive subtypes of breast cancer (22). Here, ERBB2 is linked to breast carcinoma.